文献速递淋巴瘤造血干细胞移植与细胞治疗

纳武利尤单抗治疗成人复发难治性EBV相关噬血细胞性淋巴组织细胞增生症

Nivolumab treatment of relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults.
PubMed 文献 · Blood · 2020-01-01

该回顾性分析纳入7例在华西医院以同情用药方式接受纳武利尤单抗治疗的复发难治性EBV-HLH成人患者,全部耐受治疗,6例应答,其中5例达到并维持临床完全缓解,中位随访16个月(范围11.4-18.9个月),4例血浆和细胞EBV-DNA完全清除。单细胞RNA测序显示HLH综合征与单核/巨噬细胞过度活跃及CD8 T细胞活化缺陷相关,纳武利尤单抗可扩增PD-1阳性T细胞并恢复CD8 T细胞中HLH相关脱颗粒和共刺激基因表达。

要点

  • 纳武利尤单抗单药在r/r EBV-HLH成人中耐受良好,6/7例应答。
  • 5例达临床完全缓解并维持,中位随访16个月(范围11.4-18.9个月)。
  • 4例血浆和细胞EBV-DNA完全清除,机制可能为恢复缺陷的抗EBV应答。

核心结论

  • 纳武利尤单抗单药可能治愈成人复发难治性EBV-HLH,机制可能为恢复缺陷的抗EBV免疫应答。

研究设计与样本

  • 华西医院开展的回顾性分析,纳入7例以同情用药方式接受纳武利尤单抗治疗的复发难治性EBV-HLH成人患者。

主要发现

  • 7例患者均耐受治疗,6例对纳武利尤单抗应答。
  • 5例达到并维持临床完全缓解,中位随访16个月(范围11.4-18.9个月)。
  • 4例患者血浆和细胞EBV-DNA均完全清除。
  • 单细胞RNA测序显示HLH综合征与单核/巨噬细胞过度活跃及CD8 T细胞活化程序缺陷相关。
  • 纳武利尤单抗扩增PD-1阳性T细胞并恢复CD8 T细胞中HLH相关脱颗粒和共刺激基因表达。

临床怎么用

  • 对依托泊苷方案无法有效清除病毒且未接受异基因造血干细胞移植的成人r/r EBV-HLH,可考虑纳武利尤单抗单药治疗。

局限性

  • 回顾性分析,样本量仅7例,证据级别有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Epstein-Barr virus (EBV)-associated hemophagocytic lymphohistiocytosis (EBV-HLH) is a life-threatening hyperinflammatory syndrome triggered by EBV infection. It often becomes relapsed or refractory (r/r), given that etoposide-based regimens cannot effectively clear the virus. r/r EBV-HLH is invariably lethal in adults without allogeneic hematopoietic stem cell transplantation. Here, we performed a retrospective analysis of 7 r/r EBV-HLH patients who were treated with nivolumab on a compassionate-use basis at West China Hospital. All 7 patients tolerated the treatment and 6 responded to it. Five of them achieved and remained in clinical complete remission with a median follow-up of 16 months (range, 11.4-18.9 months). Importantly, both plasma and cellular EBV-DNAs were completely eradicated in 4 patients. Single-cell RNA-sequencing analysis showed that HLH syndrome was associated with hyperactive monocytes/macrophages and ineffective CD8 T cells with a defective activation program. Nivolumab treatment expanded programmed death protein-1-positive T cells and restored the expression of HLH-associated degranulation and costimulatory genes in CD8 T cells. Our data suggest that nivolumab, as a monotherapy, provides a potential cure for r/r EBV-HLH, most likely by restoring a defective anti-EBV response.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Liu P, Pan X, Chen C, et al. Nivolumab treatment of relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults. Blood. 2020. PMID: 31914172. doi:10.1182/blood.2019003886

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。